Description Recent Traction In FDA's Development

Just as the U.S. Food & Drug Administration ("FDA"promised in its 2019 compounding priorities statement, FDA published a notice and proposed rule in the Federal Register in the past week related to bulk drug substances that can be compounded subject to the conditions of Section 503A and Section 503B of the Federal Food, Drug, & Cosmetic Act.

Read More: https://lnkd.in/fsMQp8N

https://bit.ly/2lEzfG9